Cellectis SA (Nasdaq: CLLS) to Ring The Nasdaq Stock Market Opening Bell in Celebration of IPO
March 25 2015 - 5:00AM
What:
Cellectis SA (Nasdaq:CLLS), a pioneering gene-editing company
focused on developing immunotherapies, will visit the Nasdaq
MarketSite in Times Square in celebration of its initial public
offering (IPO), which will occur today, March 25.
In honor of the occasion, André Choulika, Chief
Executive Officer and Chairman will ring the Opening
Bell.
Where:
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway –
Broadcast Studio
When:
Wednesday, March 25, 2015 – 9:15 a.m. to 9:30 a.m. ET
Cellectis SA Media Contact:
Jennifer Moore
(914) 548-5581
jennifer.moore@cellectis.com
Nasdaq MarketSite:
Christine Barna
(646) 441-5310
Christine.Barna@nasdaq.com
Feed Information:
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC
3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Social Media:
For multimedia features such as exclusive content, photo
postings, status updates and video of bell ceremonies please visit
our Facebook page at:
http://www.facebook.com/NASDAQ.
For photos from ceremonies and events visit our Instagram
Page:
http://instagram.com/nasdaq
For news tweets, please visit our Twitter page at:
http://twitter.com/nasdaq
For exciting viral content and ceremony photos visit Tumblr
Page:
http://nasdaq.tumblr.com/
Webcast: A webcast of the Nasdaq Opening Bell
will be available at: https://new.livestream.com/nasdaq/live or
http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos: To obtain a hi-resolution photograph of
the Market Open, please go to
http://www.nasdaq.com/reference/marketsite_events.stm and click on
the market open of your choice.
About Cellectis (Nasdaq:CLLS):
Cellectis is a gene-editing company focused on developing
immunotherapies based on gene edited engineered CAR-T cells
(UCART). The company’s mission is to develop a new generation of
cancer therapies based on engineered T‑cells. Cellectis capitalizes
on its 15 years of expertise in genome engineering - based on its
flagship TALEN™ products and meganucleases and pioneering
electroporation PulseAgile technology - to create a new generation
of immunotherapies. CAR technologies are designed to target surface
antigens expressed on cells. Using its life-science-focused,
pioneering genome-engineering technologies, Cellectis’ goal is to
create innovative products in multiple fields and with various
target markets. Cellectis is listed on the Nasdaq market
(ticker:CLLS) and on the NYSE Alternext market (ticker: ALCLS).
About Nasdaq:
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing,
exchange technology, listing, information and public company
services across six continents. Through its diverse portfolio of
solutions, Nasdaq enables customers to plan, optimize and execute
their business vision with confidence, using proven technologies
that provide transparency and insight for navigating today's global
capital markets. As the creator of the world's first
electronic stock market, its technology powers more than 70
marketplaces in 50 countries, and 1 in 10 of the world's securities
transactions. Nasdaq is home to more than 3,500 listed companies
with a market value of over $9.1 trillion and more than 10,000
corporate clients. To learn more, visit www.nasdaq.com/ambition or
www.business.nasdaq.com.
-NDAQA-
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Apr 2024 to May 2024
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From May 2023 to May 2024